RNA Lipoplex Formulation for GMP Manufacturing and Shelf-Life Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for formulations that deliver biologically active RNA to target tissues efficiently while maintaining product quality and biological activity, particularly for GMP-compliant manufacturing with extended shelf-life, as existing methods fail to provide stable RNA lipoplex particles for intravenous administration.
Innovation Solution
The preparation of RNA lipoplex particles involves forming liposomes from lipid solutions with concentrations above the equilibrium solubility in ethanol, using specific lipid ratios and mixing conditions, followed by GMP-compliant manufacturing and storage methods such as freezing or spray-drying to maintain RNA activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA lipoplex formulations are prepared for intravenous delivery, then biological activity is improved, but shelf-life and product stability deteriorate
Solution Approach 1:
The patent applies parameter changes by optimizing the charge ratio between cationic lipid and RNA, controlling particle size distribution, and adjusting lipid composition ratios to achieve formulations that maintain both high biological activity and improved shelf-life stability for intravenous delivery
Solution Approach 2:
The patent uses composite materials by formulating lipoplex particles with specific combinations of cationic lipids, helper lipids, and RNA in defined ratios, creating a composite structure that provides both the necessary biological activity for gene delivery and the structural stability required for extended shelf-life storage
2Manufacturing precision
If GMP-compliant manufacturing methods are implemented, then product quality is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the manufacturing process into distinct modular steps including separate lipid solution preparation, RNA preparation, controlled mixing stages, and quality control checkpoints, enabling GMP compliance through systematic process control while managing complexity through standardization
Solution Approach 2:
The patent implements parameter changes by establishing specific GMP-compliant parameters including controlled charge ratios, defined particle size ranges, standardized lipid concentrations, and documented mixing conditions, which improve product quality through consistent manufacturing while managing complexity through parameter standardization
3Stability of the object's composition
If extended shelf-life storage methods are used, then product stability is improved, but RNA activity is lost
Solution Approach 1:
The patent applies preliminary action by incorporating stability-optimizing formulations during manufacturing, including optimized lipid-RNA complexation and controlled particle formation, which preemptively protect RNA activity during subsequent extended shelf-life storage while maintaining product stability
Solution Approach 2:
The patent uses composite materials by creating stable lipoplex formulations with specific lipid compositions and charge ratios that form protective complexes around RNA, enabling extended shelf-life storage while preserving RNA biological activity through the stabilizing composite structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described methods result in RNA lipoplex particles with enhanced biological activity and stability, suitable for intravenous delivery, maintaining RNA activity and quality over extended periods.
Implementation Method 1
The RNA lipoplex particles are prepared using liposomes that are obtained by injecting a highly concentrated solution of the lipids in ethanol into water or a suitable aqueous phase
Implementation Method 2
The RNA lipoplex particle formulations described herein can be frozen or dehydrated by freeze-drying, spray-drying or related methods, enabling to obtain extended shelf-life of the products
Implementation Method 3
The RNA lipoplex particle formulations described herein can be frozen or dehydrated by freeze-drying, spray-drying or related methods
Data Source
AI summary
The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.